Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Molecules ; 26(16)2021 Aug 04.
Artigo em Inglês | MEDLINE | ID: mdl-34443306

RESUMO

This study aimed to evaluate and compare the effects of co-treatment with purified annatto oil (PAO) or its granules (GRA, Chronic®) with that of testosterone on the orchiectomy-induced osteoporosis in Wistar rats. After surgery, rats were treated from day 7 until day 45 with testosterone only (TES, 7 mg/kg, IM) or TES + PAO or GRA (200 mg/kg, p.o.). The following parameters were evaluated: food/water intake, weight, HDL, LDL, glucose, triglycerides (TG), total cholesterol (TC), alkaline phosphatase levels, blood phosphorus and calcium contents, femur weight, structure (through scanning electron microscopy), and calcium content (through atomic absorption spectrophotometry). Our results show that orchiectomy could significantly change the blood lipid profile and decrease bone integrity parameters. Testosterone reposition alone could improve some endpoints, including LDL, TC, bone weight, and bone calcium concentration. However, other parameters were not significantly improved. Co-treatment with PAO or GRA improved the blood lipid profile and bone integrity more significantly and improved some endpoints not affected by testosterone reposition alone (such as TG levels and trabeculae sizes). The results suggest that co-treatment with annatto products improved the blood lipid profile and the anti-osteoporosis effects of testosterone. Overall, GRA had better results than PAO.


Assuntos
Bixaceae/química , Carotenoides/química , Fêmur/efeitos dos fármacos , Lipídeos/sangue , Orquiectomia , Osteoporose/sangue , Osteoporose/etiologia , Extratos Vegetais/química , Óleos de Plantas/farmacologia , Testosterona/farmacologia , Animais , Peso Corporal/efeitos dos fármacos , Comportamento de Ingestão de Líquido/efeitos dos fármacos , Comportamento Alimentar/efeitos dos fármacos , Fêmur/ultraestrutura , Masculino , Substâncias Protetoras/farmacologia , Ratos Wistar
2.
J Med Food ; 20(9): 830-837, 2017 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-28731787

RESUMO

Dyslipidemia is caused by disturbances in lipid metabolism that lead to chronic elevations of serum lipids, especially low-density lipoprotein (LDL)-cholesterol and triglycerides, increasing the risk of metabolic syndrome, obesity, diabetes, atherogenic processes, and cardiovascular diseases. The oil from the fruits of Euterpe oleracea (OFEO) is rich in unsaturated fatty acids with potential for treating alterations in lipid metabolism. In this study, we aimed to investigate the effect of OFEO on hyperlipidemia induced by Cocos nucifera L. saturated fat (GSC) in Wistar rats. Chromatographic profile showed that unsaturated fatty acids account for 66.08% in OFEO, predominately oleic acid (54.30%), and saturated fatty acids (palmitic acid 31.6%) account for 33.92%. GSC-induced dyslipidemia resulted in an increase in total cholesterol, LDL-cholesterol, triglycerides, glucose, and liver and abdominal fat, as well as atherogenic processes in the thoracic aorta. OFEO treatment did not reduce hypertriglyceridemia, but did reduce total cholesterol and LDL-cholesterol, thus contributing to the antiatherogenic action of OFEO. OFEO treatment inhibited the formation of atheromatous plaques in the vascular endothelium of the treated rats, as well as those who were treated with simvastatin. The results obtained suggest that OFEO has an antiatherogenic effect in a rat model of dyslipidemia.


Assuntos
Cocos/efeitos adversos , Dislipidemias/dietoterapia , Euterpe/química , Ácidos Graxos/efeitos adversos , Óleos de Plantas/metabolismo , Animais , Aorta Torácica/metabolismo , Colesterol/sangue , LDL-Colesterol/sangue , Cocos/química , Dislipidemias/etiologia , Dislipidemias/metabolismo , Ácidos Graxos/metabolismo , Frutas/química , Frutas/metabolismo , Humanos , Masculino , Ratos , Ratos Wistar , Triglicerídeos/sangue
3.
Biomed Pharmacother ; 90: 542-547, 2017 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-28402923

RESUMO

OBJECTIVES: Dyslipidemias are defined as changes in lipid metabolism that have abnormal concentrations of lipids or lipoproteins in the bloodstream. Chronic increase in triglyceride and low-density lipoprotein (LDL-c) levels are known as risk factors for the atherogenesis process as well as other cardiovascular diseases (CVDs). The magnitude of the problems caused by dyslipidemias impels research by new agents that act in the prevention and control. Thus, products from the Amazonian biodiversity, such as Euterpe oleracea oil (OFEO), rich in unsaturated fatty acids (UFAs), constitutes a study source for the treatment of alterations in lipid metabolism. METHODS: The present study aims to investigate the effect of OFEO treatment in rats with Triton-induced dyslipidemia (Tyloxapol WR1339). RESULTS: The physicochemical and chromatographic results confirmed the chemical composition of OFEO with a predominance of UFAs (67.83%), with Oleic acid being the majority (54.32%). At Triton-induced dyslipidemia, the animals treated with OFEO and Simvastatin showed a significant reduction in total cholesterol levels, with values ​​of 121.7±29.5 (p<0.01) and 96.6±17.6mg/dL (p<0.001), respectively. OFEO also significantly reduced LDL-c levels (p<0.01) and triglycerides (p<0.001). OFEO and Simvastatin improved the lipid profile by significantly increasing (p<0.05) the high-density lipoprotein (HDL) values. CONCLUSIONS: Therefore, it is concluded that the OFEO treatment used in the conditions of this study had a beneficial effect on dyslipidemia, acting as antihypercholesterolemic and antihypertriglyceridemic, thus possibly contributing as a preventive agent for CVDs.


Assuntos
Dislipidemias/tratamento farmacológico , Euterpe/química , Óleos de Plantas/farmacologia , Animais , Aterosclerose/sangue , Aterosclerose/tratamento farmacológico , Doenças Cardiovasculares/sangue , Doenças Cardiovasculares/tratamento farmacológico , HDL-Colesterol/sangue , Dislipidemias/sangue , Hipolipemiantes/farmacologia , Lipídeos/sangue , Lipoproteínas/sangue , Lipoproteínas LDL/sangue , Masculino , Ratos , Ratos Wistar , Sinvastatina/farmacologia , Triglicerídeos/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA